Do Glucagon-like peptide-1 (GLP-1) receptor agonists cause sweating?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

GLP-1 Receptor Agonists Do Not Cause Sweating

Sweating is not a recognized adverse effect of GLP-1 receptor agonists based on current clinical evidence and guidelines. The documented side effect profile does not include sweating or hyperhidrosis among the common, uncommon, or rare adverse events 1.

Established Adverse Effect Profile

The well-documented side effects of GLP-1 receptor agonists include:

Gastrointestinal Effects (Most Common)

  • Nausea, vomiting, and diarrhea occur in 15-20% of patients and are the most frequently reported adverse effects 1
  • These gastrointestinal symptoms typically occur during initial treatment and gradually diminish over several weeks to months with dose titration 1
  • Dyspepsia, gastroesophageal reflux, and constipation are also documented 1
  • Abdominal pain is commonly reported 2

Cardiovascular Effects

  • Heart rate increases by approximately 5 beats per minute, but this has not been associated with higher blood pressure or other adverse cardiovascular events 1
  • Cardiac arrhythmia or tachycardia may occur but is unusual to be symptomatic 1

Other Common Effects

  • Injection site reactions occur in less than 1% of patients 1
  • Headache and nasopharyngitis are documented but rarely lead to discontinuation 3
  • Hypersensitivity reactions including anaphylaxis and rashes have been reported 2

Serious but Rare Effects

  • Pancreatitis and biliary disease may occur 1, 2
  • Acute kidney injury, primarily through hemodynamic derangement from severe gastrointestinal losses 2, 3
  • Increased risk of diabetic retinopathy 2
  • Hypoglycemia when combined with sulfonylureas or insulin 1, 3

Clinical Implications

If a patient reports sweating while on GLP-1 therapy, investigate alternative causes rather than attributing it to the medication 1. Consider:

  • Hypoglycemia if the patient is on concurrent insulin or sulfonylureas 1, 3
  • Dehydration from gastrointestinal losses (nausea, vomiting, diarrhea) 2, 3
  • Unrelated medical conditions or other medications
  • Autonomic dysfunction from underlying diabetes itself

The absence of sweating in the documented adverse effect profile across multiple high-quality guidelines and comprehensive reviews strongly indicates this is not a medication-related symptom 1, 2, 3, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

GLP-1 agonists: A review for emergency clinicians.

The American journal of emergency medicine, 2024

Research

Adverse Effects of GLP-1 Receptor Agonists.

The review of diabetic studies : RDS, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.